Drug Trial Radar · NCT03698513
A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Sep 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
113
Actual
Start
Oct 4, 2018
Primary completion
Feb 19, 2019
Study completion Feb 19, 2019
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will investigate the safety and interaction of BMS-986177 in healthy volunteers, when administered with Aspirin and/or Clopidogrel
Conditions
- Healthy Volunteers
Interventions
BMS-986177Drug
BMS-986177 capsule
Placebo (for BMS-986177)Other
BMS-986177 placebo match capsule
ClopidogrelDrug
Clopidogrel tablet
AspirinDrug
Aspirin tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: Up to Day 33
- Incidence of Serious Adverse Events (SAEs)Time frame: Up to Day 95
- Incidence of Adverse Events (AEs) leading to discontinuationTime frame: Up to Day 33
- Number of participants with vital sign abnormalitiesTime frame: Up to Day 33
- Number of participants with 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Up to Day 33
- Number of participants with clinical laboratory abnormalitiesTime frame: Up to Day 33
- Number of participants with physical examination abnormalitiesTime frame: Up to Day 33
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Development, LP
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.